CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Silverlon +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05163392
NCT05163392N/ACompleted
CompareCT.gov

A Silver Lining in the VAD Sky: Impact of Silver Dressing on LVAD Associated Driveline Infection

University of California, San Francisco·interventional·Posted Dec 20, 2021·Updated Feb 13, 2026

In Brief

A clinical study evaluating Silverlon and Control for LVAD (Left Ventricular Assist Device) Driveline Infection. Completed, enrolled 25 participants across 1 site.

Detailed Summary

The investigators propose to conduct a prospective randomized trail (RCT) of a driveline management protocol. The study will be initiated at UCSF from January 1st 2022 to December 31st 2022 as a pilot to be extended to other sites with the ultimate goal to develop a multi-center RCT. The driveline dressing protocol studied will include a silver-based dressing barrier as well as a dressing change protocol and material designed to reduce the risk of driveline dressing induced dermatitis and allergies. Assessment will include DLI rates, DLI speciation, dermatitis rate, comfort, ease of use, compliance and cost

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLVAD (Left Ventricular Assist Device) Driveline Infection
CountriesUnited States
CollaboratorsInternational Consortium of Circulatory Assist Clinicians

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 20, 2021
Enrollment StartFeb 1, 2022
Primary CompletionDec 1, 2024
Study CompletionJan 26, 2026
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 4.5 years ago

Interventions

Silverlondevice

SIlver-plated biopatch

Controldevice

Tegaderm without biopatch